Liquid Chromatography Mass Spectrometry (LCMS) Market to Surpass USD 18,020 Mn by 2033

The Liquid Chromatography Mass Spectrometry (LCMS) Market, estimated at USD 8,169 Mn in 2026, is expected to exhibit a CAGR of 12.0% and reach USD 18,020 Mn by 2033.

Global Liquid Chromatography Mass Spectrometry (LCMS) Market, by Type (Single Quadrupole LC-MS, Triple Quadrupole LC-MS, and Ion Trap LC-MS), by Sensitivity (High Flow, Micro Flow, and Nano Flow), by End User (Biotechnology and Pharmaceutical Industry, Hospital and Research Laboratories, and Academic and Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) it is expected to be valued at USD 8,169 Mn in 2026, and is expected to exhibit a CAGR of 12.0% over the forecast period (2026 – 2033), as highlighted in a new report published by . Increasing research and development expenditure in the healthcare sector and increasing product launches by market players are expected to drive the market growth Increasing product launches by market players, in order to offer advanced solutions for efficient analysis of samples in the biotechnology and pharmaceutical industry, and other sectors is expected to drive the Liquid Chromatography Mass Spectrometry (LCMS) Market growth. For instance, in June 2017, Thermo Fisher launched a fully automated analyzer, Cascadion SM clinical analyzer system with selectivity and sensitivity of liquid chromatography-tandem mass spectrometry (LC-MS/MS). The fully automated analyzer can be customized easily to be compatible with the laboratory information systems. Moreover, initiatives taken by regulatory authorities regarding adoption of LCMS technique for testing and analysis in the biopharmaceutical industry is expected to drive growth of the LCMS market over the forecast period. For instance, in October 2019, the U.S. Food and Drug Administration (FDA) recommended pharmaceutical companies to use Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) for testing N-nitrosodimethylamine (NDMA) in ranitidine products. The NDMA is found to be carcinogenic in nature.

Browse 28 Market Data Tables and 23 Figures spread through 186 Pages and in-depth TOC on ‘Liquid Chromatography Mass Spectrometry (LCMS) Market’- Global Forecast to 2033, by Type (Single Quadrupole LC-MS, Triple Quadrupole LC-MS, and Ion Trap LC-MS), by Sensitivity (High Flow, Micro Flow, and Nano Flow), by End User (Biotechnology and Pharmaceutical Industry, Hospital and Research Laboratories, and Academic and Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) To know the latest trends and insights prevalent in this market, click the link below: https://www.coherentmarketinsights.com/market-insight/liquid-chromatography-mass-spectrometry-market-3102 Furthermore, key players and other organizations are focused on strategic collaborations to offer training programs for researchers, scientists, and other personnel, in order to boost drug discovery in emerging economies. For instance, in August, 2019, Jomo Kenyatta University of Agriculture and Technology (JKUAT), Kenya held a training session for researchers from ten African countries for liquid chromatography mass spectrometry (LC-MS) training, to help analyze live molecules in food, medicine, and organic compounds. The training was co-funded by the Royal Society of Chemistry (RSC) and GlaxoSmithKline (GSK), and the Pan Africa Chemistry Network (PACN). The key players operating in the market are focused on adopting acquisition and collaboration strategies, in order to expand their product offerings in potential markets. For instance, in September 2019, Thermo Fisher Scientific Inc. and Cedars-Sinai entered a collaboration for developing advanced liquid chromatography mass spectrometry workflows for screening and targeted quantitation of protein-based biomarkers for complicated diseases. 

Key Development for the Liquid Chromatography Mass Spectrometry (LCMS) Market

• In June 2026, At ASMS 2026, major mass spectrometry vendors introduced advanced instruments and workflow solutions focused on higher sensitivity, faster multiomics, improved data handling, and AI-enabled analysis. Launches from Thermo Fisher, Waters, Bruker, SCIEX, Agilent, and Shimadzu highlight growing demand for integrated LC-MS platforms that help laboratories process complex samples efficiently and generate more confident scientific insights across regulated and research settings.
• In April 2026, Shimadzu, leading-edge science and technologies company in analytical and measuring instruments launched the Nexera X4 UHPLC, a next-generation ultra-high-performance liquid chromatograph designed for ultra-fast, high-sensitivity analysis. The system uses low-dispersion architecture, Nexflow technology, and advanced fluid control to deliver sharper peaks, stronger separation performance, and reliable high-speed results. Its LC/MS compatibility and reduced solvent consumption support pharmaceutical, food, environmental, and chemical laboratories seeking faster throughput, improved analytical confidence, and more efficient workflows across research, quality control, and regulated testing applications. (Source: Shimadzu)
• In June 2026, Waters Corporation, an American company introduced the Xevo MRT P10 Mass Spectrometer at ASMS 2026, targeting high-throughput multiomics, bioanalysis, and biopharmaceutical laboratories. The benchtop HRMS system delivers up to 20x higher MS/MS sensitivity, 2x faster acquisition speeds, and advanced acquisition modes for targeted and untargeted analysis. It also identifies up to 40% more lipids by LC-MS/MS, supporting biomarker discovery, disease pathway research, and faster therapeutic insights.
• In April 2026, Merck & Co., Inc., pharmaceutical company launched its first bio-based solvent portfolio for high-performance liquid chromatography on April 21, 2026, targeting greener analytical workflows. Made from renewable feedstocks, the patent-pending solvents reduce average CO2-equivalent emissions by 25.9% versus fossil-based alternatives while maintaining established HPLC and LC-MS performance. Drop-in replacements for acetonitrile, methanol and ethanol enable laboratories to improve sustainability without redeveloping methods, supporting pharmaceutical R&D, quality control, environmental monitoring and diagnostics applications.

Key Takeaways of the Liquid Chromatography Mass Spectrometry (LCMS) Market

• The global Liquid Chromatography Mass Spectrometry (LCMS) Market is expected to exhibit a CAGR of 12.0% over the forecast period, owing to product launches by market players. For instance, in 2018, Shimadzu Corporation launched Nexera Mikros, a micro flowrate-compatible liquid chromatograph mass spectrometer which provides ten times higher sensitivity.
• The micro flow segment held a dominant position in the Liquid Chromatography Mass Spectrometry (LCMS) Market in 2018, owing to its vast application in research which includes proteomics, biomarker discovery, bioanalysis, and environmental analysis, which is attributed to its higher sensitivity
• The biotechnology and pharmaceutical industries segment held a dominant position in the Liquid Chromatography Mass Spectrometry (LCMS) Market in 2018, owing to increasing innovations to accelerate drug development. For instance, in May 2018, SCIEX launched BioPharmaView Software 3.0 solution for complete LC-MS multiple attribute methodology (MAM) workflow, which enables detailed characterization of biologics for use by biopharma researchers.
• Key players operating in the global Liquid Chromatography Mass Spectrometry (LCMS) Market include Danaher Corporation, PerkinElmer, Inc., Waters Corporation, Bruker Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Shimadzu Corporation, JEOL Ltd., and Newomics, Inc. and Others